Topics

Ignyta Inc. Company Profile

10:30 EST 27th January 2020 | BioPortfolio

At Ignyta, we fight cancer – a formidable opponent that manifests as thousands of different molecularly defined diseases and takes away millions of lives globally, every year. In this fight, our big hairy audacious goal (BHAG) is not just to shrink tumors but to eradicate residual disease – the source of cancer relapse and recurrence – in precisely defined patient populations by 2030. We will work tirelessly to achieve this BHAG by pursuing an integrated therapeutic (Rx) and companion diagnostic (Dx) strategy for treating cancer patients. Our Rx efforts are focused on discovering, in-licensing or acquiring, then developing and commercializing, molecularly targeted therapies that, sequentially or in combination, are foundational for eradicating residual disease. Our Dx efforts aim to pair these product candidates with biomarker-based companion diagnostics that are designed to precisely identify, at the molecular level, the patients who are most likely to benefit from the therapies we develop. We believe that only through this integrated Rx/Dx approach can we succeed in this fight. For more information, please visit: www.ignyta.com.


News Articles [4 Associated News Articles listed on BioPortfolio]

Japan first to approve Roche’s Vitrakvi rival larotrectinib

Acquired in Ignyta buyout

Executive of the Year: Josh Bilenker, Loxo Oncology

Along with other recently acquired cancer companies like Ignyta and Array, Loxo proved out a drug development model that Bilenker likens to baseball's "moneyball" thesis. 

Boundless Bio Launches With $46m And Novel Oncology Focus On Extrachromosomal DNA

Former Ignyta executive Zachary Hornby wasn't wowed by immuno-oncology pitches when looking for his next cancer drug development company, but...   

Japan approves Roche's tumour agnostic cancer drug Rozlytrek

Japan has become the first country to approve Roche’s personalised cancer drug Rozlytrek (entrectinib). Roche added entrectinib to its pipeline through its $1.7 billion buyout of Ignyta at the end ...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [2 Associated Companies listed on BioPortfolio]

Ignyta, Inc.

Ignyta, Inc., located in San Diego, California, is a personalized medicine company developing revolutionary new products and services to customize diagnosis and treatment of patie...

Ignyta Inc.

At Ignyta, we fight cancer – a formidable opponent that manifests as thousands of different molecularly defined diseases and takes away millions of lives globally, every year...

More Information about "Ignyta Inc." on BioPortfolio

We have published hundreds of Ignyta Inc. news stories on BioPortfolio along with dozens of Ignyta Inc. Clinical Trials and PubMed Articles about Ignyta Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Ignyta Inc. Companies in our database. You can also find out about relevant Ignyta Inc. Drugs and Medications on this site too.

Quick Search

Relevant Topics

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...


Corporate Database Quicklinks



Searches Linking to this Company Record